Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 26, 2007

Ipsen Licenses Therapy to Galderma for $40M

  • Ipsen and Galderma entered into a partnership for the development, promotion, and distribution of Ipsen’s botulinum toxin type A, Dysport®, for use in aesthetic medicine indications in Europe and certain other territories. Dysport® acts to block acetylcholine release at motor nerve ends and reduces muscular spasm.

    Under the terms of this agreement, Ipsen granted Galderma exclusive rights to develop, promote, and distribute a specific formulation for the aesthetic medicine indications of its botulinum toxin type A product in the European Union, Russia, and certain territories of the Middle East and Eastern Europe. In addition, Ipsen also granted Galderma first rights of negotiation for aesthetic medicine indications in the rest of the world, excluding the United States, Canada, and Japan, as well as rights for future formulations.

    Galderma will pay Ipsen an upfront payment of Euro10 million and up to Euro20 million in additional payments upon the achievement of certain milestones, including market approvals and product launches in certain territories, and an additional payment, to be negotiated, with respect to Russia.

    Ipsen will manufacture and supply Galderma’s finished product at a fixed supply price. In addition, Galderma will pay royalties to Ipsen. Ipsen will own all regulatory approvals and all data arising from development activities, while Galderma will own the trademark and/or trademark rights in aesthetic medicine indications.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »